Professor
Director, Johns Hopkins Center for Global Health
BS, University of Notre Dame, 1969 MSc, University of Notre Dame, 1970 MD, Northwestern University, 1974
School of Medicine
Dept. of Medicine
Infectious Diseases
Bloomberg School of Public Health: Epidemiology, Molecular Microbiology and Immunology, International Health, and Pathology; School of Nursing
Center for Global Health
- Investigation of the epidemiology, pathogenesis, and clinical features of HIV/AIDS internationally. Interaction between STDs and tropical diseases on the natural history and spread of HIV/AIDS in developing countries. Recent research has examined the viral kinetics and transmission probabilities of HIV among discordant couples with the subsequent design and application of interventions including therapy to prevent transmission of HIV. Molecular studies have mapped the molecular epidemic of HIV on a global basis, linking virologic changes to the spread of HIV and measuring the demographic impact of the epidemic. Implementation of clinical care programs for HIV, STDs, and other infectious diseases while advocating for improved clinical education for African physicians and implementing public health policy from these and other research findings.
-
Dr. Quinn was one of the first to demonstrate that non-invasive screening for STDs by use of molecular diagnostic assays could extend public health efforts to control STDs to non-clinic settings. This innovative approach, when coupled with his findings on the role of STDs as co-factors in enhancing HIV transmission, has led to one of the current basic tenets of the global AIDS control program; the treatment of STDs to slow the transmission of HIV. Currently directs several field-based programs in Africa and Asia, utilizing community-based STD treatment linked with HIV prevention projects. Founding member of the Academic Alliance for AIDS Care and Prevention in Africa; founding director of the Johns Hopkins Center for Global Health.
- HIV, AIDS, STDs, STI, epidemiology, global health, infectious diseases, pathogenesis, viral infections, chlamydia, developing countries, resource-limited settings
- 1969-72 U.S.P.H.S. Research Training Award from NIAID, NIH
-
1970-74 Northwestern Univ Medical School Health Professions Award
-
1979-81 U.S.P.H.S. Career Development Award
-
1980 U.S.P.H.S. Special Assignment Award
-
1985 U.S.P.H.S. Commendation Award, NIAID, NIH
-
1987 A.O.A. Epidemiology Research Award
-
1987 State of Maryland Annual Distinguished Physician Lectureship
-
1988 U.S.P.H.S. Outstanding Service Award, NIAID, NIH
-
1989 U.S.P.H.S. Outstanding Unit Citation, NIAID, NIH
-
1990 UCLA Lester Breslow Distinguished Lectureship Epidemiology
-
1990 UCLA John F. Kessel Distinguished Lectureship Tropical Med
-
1990 University of Florida Commemorative Award Presentation
-
1994 Charles C. Shepard Award Outstanding Scientific Publication
-
1994 National Center for Infectious Diseases, Centers for Disease Control and Prevention Special Recognition Award
-
1994 James H. Nakano Citation Outstanding Scientific Publication
-
1995 American College of Preventive Medicine Award for Best Scientific Presentation
-
1995 U.S.P.H.S. Meritorious Service Award
-
1996 Stephen Gross HIV Lectureship Award, Cedars-Sinai Hospital
-
1996 U.S.P.H.S. Meritorious Service Award, NIAID, NIH
-
1996-99 Best Doctors in America, Infectious Diseases, HIV and STDs
-
1998 Special Opening Plenary Lecture, IDSA
-
1998 U.S.P.H.S. Bicentennial Unit Commendation
-
1999 ASTDA Lifetime Achievement Award
-
1999 Indiana Univ School of Medicine Award in Infectious Diseases
-
1999 U.S.P.H.S. Distinguished Service Award
-
2000 Duncan Catterall Memorial Lecture, British Association for Sexual Health and HIV
-
2000 Sommer Memorial Lecture, Portland, Oregon
-
2000 U.S.P.H.S. Distinguished Service Award
-
2000 IAPAC Heroes in Medicine Award
-
2002 Dowling Memorial Visiting Professorship, University of Illinois Medical Ctr
-
2003 Harold C. Neu Visiting Professorship, Columbia University
-
2003 Harry C. Dascomb Memorial Visiting Scholar Lectureship, Louisiana State University
-
2003 Plenary Lectdureship, 12th Annual Canadian Conference on HIV/AIDS Research, Nova Scotia, Canada
-
2004 Morris M. Gollow Keynote Lectureship, Australasian Sexual Health Conference
-
2004 Elected Member, Institute of Medicine, National Academy of Sciences
-
2007 Elected Fellow, American Association for the Advancement of Science
Research Projects
A Randomized, controlled trial of Acyclovir prophylaxis versus placebo among HIV/HSV-2 co-infected individuals (through the Rakai Health Sciences Program)
Interventions that slow HIV-1 disease progression among persons with CD4+ counts above 250 cells/µL could postpone the need for antiretroviral therapy (ART) and prolong life-expectancy for HIV-infected persons. Herpes simplex virus type 2 (HSV-2) has been shown to up-regulate HIV-1 replication...
A randomized, controlled trial of short cycle intermittent versus continuous HAART for the treatment of chronic HIV infection in Uganda
Although highly active antiretroviral therapy (HAART) has been successful in suppressing plasma HIV RNA levels and providing significant clinical benefit in infected patients, it does not eradicate HIV infection. It is now clear that virus replication persists despite undetectable plasma viremia...
Algorithms for improved cross sectional incidence testing for HIV
Using a combination testing methods to improve accuracy of identifying samples from newly infected individuals based on biologic properties of the immune system that evolve over the course of infection. The goal is to generate a widely applicable assays for the use in HIV incidence monitoring on...
ARV effects on HIV epidemiology & behaviors, Rakai Uganda (through the Rakai Health Sciences Program)
The provision of HIV antiretroviral (ARV) therapy in Africa will have beneficial health and social effects, but will present many challenges. Since the drugs are now being initiated in Uganda, we have a narrow window of opportunity to assess the population-level impact of ARVs on HIV transmission...
Effects of Male Circumcision (MC) in the Community, with Nested Clinical Research
To assess the effects of male circumcision (MC) program roll out on HIV incidence in communities, on MC acceptance by men and women, and on behaviors in men and women. Nested research includes studies on post-MC surgical wound healing, post-surgical HIV shedding in HIV+ men who request and...
Evaluation of a pilot cluster-randomized mobile phone intervention used by peer educators in a rural antiretroviral care program in Rakai, Uganda (through the Rakai Health Sciences Program)
To evaluate the feasibility of mobile phone technology used by peer educators as a strategy to facilitate communication and improve HIV care in a rural, resource-limited setting.
Fever in Ugandan Outpatients: A Microbiological Survey of Causative Organisms and Clinical Determinants (through the Rakai Health Sciences Program)
In malaria-endemic areas, fever is often assumed to stem from malaria. The objective of this study was to determine the microbiological causes of fever among HIV+ and HIV-Ugandans attending outpatient clinics.
Adult subjects attending rural outpatient clinics Nov 1 2006-April 11 2007 with...
HIV Dementia in Uganda: Response to Highly Active Antiretroviral Therapy
STUDY RATIONALE: To date, over 16 million people in Africa have died of AIDS and approximately 26.6 million or almost 70% of the world''''s total of HIV-infected people reside in Sub-Saharan Africa. Given that 40 million people globally are HIV seropositive as of the end of 2003, HIV dementia ...
Infectious Diseases Institute At Makerere University in Kampala Uganda
HIV Clinical Care, research and training in Uganda. Major research activities include ARV cohort, studies of IRIS, Kaposi''''s sarcoma, Neurologic complications of HIV, African clinical pharmacology, HIV resistance, and hepatitis B. Opportunities exist for training in the HIV Clinic directed by...
International Studies Of Acquired Immune Deficiency Syndrome (AIDS)
HIV/AIDS is a global pandemic with nearly 40 million individuals living with HIV infection worldwide. The objectives of this project are to define the unique epidemiological, clinical, virologic, and immunologic features of HIV infection in developing countries, to determine the viral kinetics...
Laboratory support for Rakai Program research activities (through the Rakai Health Sciences Program)
The Rakai Program has been designated as one of only three Intramural Program International Center for Excellence in Researh (ICER) world-wide. The award provides ongoing laboratory support (equipment, technical assistance, supplies) for Rakai research priorities, and fosters collaboration...
NIH/Johns Hopkins Bench to Bedside Project: Hepatitis B and HIV Co-Infection
The NIH Bench to Bedside program provides a unique opportunity to develop a systematic research program to improve understanding and management of HIV and hepatitis B (HBV) co-infection, from ‘bench’ to ‘bedside’ to ‘bush’. Building on the existing NIH/NIAID International Center for Excellence in...
Partnership for Building the Capacity of Makerere University to Improve Health Outcomes in Uganda
The ultimate goal of this project is to improve health outcomes by building and sustaining capacity at MU to address current and evolving health priorities in Uganda and the East Africa Region through strategic partnerships with JHU and key national and international stakeholders. The faculties...
Post-trial surveillance, male circumcision for HIV prevention (through the Rakai Health Sciences Program)
To conduct post-trial surveillance in men enrolled into a randomized controlled trial of male circumcision for HIV prevention in HIV-negative men.
For more information on the Rakai Health Sciences Program, please visit our website: www.jhsph.edu/rakai/
Prevention of Maternal -to- Infant HIV Transmission In India
This study is a randomized, 2-arm, open-labeled trial among HIV-infected mothers and their breast-fed infants designed to compare the safety and efficacy of standard maternal/infant single dose nevirapine (NVP) (Arm 1) to the single dose NVP regimen plus low-dose daily infant NVP for 6 weeks post...
Response to Retroviral Therapy in the Mulago Hospital AIDS Clinic/Infectious Disease Institute: A Prospective Evaluation of Alternative, Inexpensive Laboratory Techniques to Measure CD4 Lymphocyte Count and HIV Viral Load
A prospective comparison of two manual bead-based assays (Dynabeads and Cytospheres) to immunologic response by flow cytometry and virologic response by RT-PCR at a public, urban clinic in Kampala, UgandaLaboratory-based monitoring of antiretroviral therapy (ART) is essential, but adds a...
The effect of HIV subtype and coreceptor tropism on transmission and progression of diseases
Abstract not available
Validation of algorithm for monitoring the virological efficacy of antiretroviral therapy in Africa
Routine virological monitoring of HIV-infected patients on antiretroviral therapy (ART) is not currently affordable or available in most African HIV clinics using standard methods such as RNA polymerase chain reaction (PCR). Alternative cheaper technologies to quantify the viral load are still...
Validation of filter paper methodology to perform HIV-1 PCR and HIV-1 genotyping for patients on HAART
Introduction and background information
Quantification of HIV RNA and the detection of genotypic resistance is usually performed on liquid plasma. The cost and technical requirements for a laboratory to offer this test are substantial. Therefore facilities to measure viral load are only...
Viral and immunologic factors contributing to the lack of HIV transmission among couples (through the Rakai Health Sciences Program)
Understanding the factors that contribute to the transmission of human immunodeficiency virus (HIV) infection is of great importance for the development of preventive and therapeutic strategies. Evidence suggests that a number of host immunologic and virologic factors play critical roles in...
Yearly Mass Treatment C. Trachomatis for Trachoma Control in Tanzania
Country trachoma control programs are currently mass treating trachoma endemic communities every year using single dose azithromycin, with no evidence base for how long treatment must continue to reach these goals, or the optimal clinical marker with which to monitor progress. The World Health...
- Kamya MR, Mayanja-Kizza H, Kambugu A, Bakeera-Kitaka S, Semitala F, Mwebaze-Songa P, Castelnuovo B, Schaefer P, Spacek LA, Gasasira AF, Katabira E, Colebunders R, Quinn TC, Ronald A, Thomas DL, Kekitiinwa A, Academic Alliance for AIDS Care and Prevention in Africa (2007) Predictors of long-term viral failure among ugandan children and adults treated with antiretroviral therapy. J Acquir Immune Defic Syndr 46:187-93.
-
Kagaayi J, Makumbi F, Nakigozi G, Wawer MJ, Gray RH, Serwadda D, Reynolds SJ (2007) WHO HIV clinical staging or CD4 cell counts for antiretroviral therapy eligibility assessment? An evaluation in rural Rakai district, Uganda. AIDS 21:1208-10. [PubMed]
-
Oyugi JH, Byakika-Tusiime J, Ragland K, Laeyendecker O, Mugerwa R, Kityo C, Mugyenyi P, Quinn TC, Bangsberg DR (2007) Treatment interruptions predict resistance in HIV-positive individuals purchasing fixed-dose combination antiretroviral therapy in Kampala, Uganda. AIDS 21:965-71.
-
Quinn TC (2007) Circumcision and HIV transmission. Curr Opin Infect Dis 20:33-8.
-
Moss WJ, Scott S, Mugala N, Ndhlovu Z, Beeler JA, Audet SA, Ngala M, Mwangala S, Nkonga-Mwangilwa C, Ryon JJ, Monze M, Kasolo F, Quinn TC, Cousens S, Griffin DE, Cutts FT (2007) Immunogenicity of standard-titer measles vaccinein HIV-1-infected and uninfected Zambian children: an observational study. J Infect Dis 196:347-55.
-
Gray RH, Makumbi F, Serwadda D, Lutalo T, Nalugoda F, Opendi P, Kigozi G, Reynolds SJ, Sewankambo NK, Wawer MJ (2007) Limitations of rapid HIV-1 tests during screening for trials in Uganda: diagnostic test accuracy study. BMJ 335:188.
-
Gray RH, Li X, Kigozi G, Serwadda D, Nalugoda F, Watya S, Reynolds SJ, Wawer M (2007) The impact of male circumcision on HIV incidence and cost per infection prevented: a stochastic simulation model from Rakai, Uganda. AIDS 21:845-50. [PubMed]
-
Gray RH, Kigozi G, Serwadda D, Makumbi F, Watya S, Nalugoda F, Kiwanuka N, Moulton LH, Chaudhary MA, Chen MZ, Sewankambo NK, Wabwire-Mangen F, Bacon MC, Williams CF, Opendi P, Reynolds SJ, Laeyendecker O, Quinn TC, Wawer MJ (2007) Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet 369:657-66.
-
Calmy A, Ford N, Hirschel B, Reynolds SJ, Lynen L, Goemaere E, Garcia de la Vega F, Perrin L, Rodriguez W (2007) HIV viral load monitoring in resource-limited regions: optional or necessary? Clin Infect Dis 44:128-34.
-
Blake DR, Quinn TC, Gaydos CA (2008) Should asymptomatic men be included in chlamydia screening programs? Cost-effectiveness of chlamydia screening among male and female entrants to a national job training program. Sex Transm Dis 35:91-101.
-
Chang LW, Kagaayi J, Nakigozi G, Packer AH, Serwadda D, Quinn TC, Gray RH, Bollinger RC, Reynolds SJ (2008) Responding to the human resource crisis: peer health workers, mobile phones, and HIV care in Rakai, Uganda. AIDS Patient Care STDS 22:173-4.
-
Gamiel JL, Tobian AA, Laeyendecker OB, Reynolds SJ, Morrow RA, Serwadda D, Gray RH, Quinn TC (2008) Improved performance of enzyme-linked immunosorbent assays and the effect of human immunodeficiency virus coinfection on the serologic detection of herpes simplex virus type 2 in Rakai, Uganda. Clin Vaccine Immunol 15:888-90.
-
Kiwanuka N, Laeyendecker O, Robb M, Kigozi G, Arroyo M, McCutchan F, Eller LA, Eller M, Makumbi F, Birx D, Wabwire-Mangen F, Serwadda D, Sewankambo NK, Quinn TC, Wawer M, Gray R (2008) Effect of human immunodeficiency virus Type 1 (HIV-1) subtype on disease progression in persons from Rakai, Uganda, with incident HIV-1 infection. J Infect Dis 197:707-13.
-
Moss WJ, Fisher C, Scott S, Monze M, Ryon JJ, Quinn TC, Griffin DE, Cutts FT (2008) HIV type 1 infection is a risk factor for mortality in hospitalized Zambian children with measles. Clin Infect Dis 46:523-7.
-
Ngo TD, Laeyendecker O, La H, Hogrefe W, Morrow RA, Quinn TC (2008) Use of commercial enzyme immunoassays to detect antibodies to the herpes simplex virus type 2 glycoprotein G in a low-risk population in Hanoi, Vietnam. Clin Vaccine Immunol 15:382-4.
-
Ngo TD, Laeyendecker O, Morrow RA, Lai S, Quinn TC (2008) Comparison of three commercial immunoassays for detection of herpes simplex virus type 2 antibodies in commercial sex workers in yunnan province, china. Clin Vaccine Immunol 15:1301-3.
-
Persaud D, Ray SC, Kajdas J, Ahonkhai A, Siberry GK, Ferguson K, Ziemniak C, Quinn TC, Casazza JP, Zeichner S, Gange SJ, Watson DC (2007) Slow human immunodeficiency virus type 1 evolution in viral reservoirs in infants treated with effective antiretroviral therapy. AIDS Res Hum Retroviruses 23:381-90.
-
Scott S, Moss WJ, Cousens S, Beeler JA, Audet SA, Mugala N, Quinn TC, Griffin DE, Cutts FT (2007) The influence of HIV-1 exposure and infection on levels of passively acquired antibodies to measles virus in Zambian infants. Clin Infect Dis 45:1417-24.
-
Summerton J, Riedesel M, Laeyendecker O, Gaydos C, Maldeis NE, Hardick A, Morrow RA, Quinn TC (2007) Effect of sexually transmitted disease (STD) coinfections on performance of three commercially available immunosorbent assays used for detection of herpes simplex virus type 2-specific antibody in men attending Baltimore, Maryland, STD clinics. Clin Vaccine Immunol 14:1545-9.
-
Waters L, Kambugu A, Tibenderana H, Meya D, John L, Mandalia S, Nabankema M, Namugga I, Quinn TC, Gazzard B, Reynolds SJ, Nelson M (2007) Evaluation of filter paper transfer of whole-blood and plasma samples for quantifying HIV RNA in subjects on antiretroviral therapy in Uganda. J Acquir Immune Defic Syndr 46:590-3.
|
|
